GEn1E Lifesciences Inc.
Private Company
Clinical-stage multi-target company with an AI Platform to accelerate therapies for rare & inflammatory diseases.
Biotechnology Research
Palo Alto, California
11-50 employees
Founded 2018
About GEn1E Lifesciences Inc.
GEn1E Lifesciences is a clinical-stage biotechnology company dedicated to developing first-in-class medications for rare and inflammatory diseases using their proprietary AI-powered end-to-end platform. The company designs dual-signal kinase modulators and precision therapies, with their lead candidate GEn-1124 currently in Phase 2 clinical trials for ARDS treatment. They primarily serve pharmaceutical companies, healthcare providers, and government agencies like BARDA through partnerships and licensing agreements.
Company Classification
Customer Types
B2BB2G
Business Models
ProductsLicensing
Product & Service Types
AI-powered drug discovery platformDual-signal kinase modulatorsClinical-stage therapeutics
Funding
Total Funding
$17.03M
No. of Funding Rounds
6
Customers
| Customer | Success Story | Source |
|---|---|---|
| Licensed a set of p38α‑specific compounds from GEn1E Lifesciences to develop treatments for acute respiratory distress syndrome and other inflammatory diseases. | ||
| Entered into a partnership with GEn1E Lifesciences to develop and potentially commercialize novel dual‑signal modulators for rare and inflammatory diseases. | ||
Nice Try Sign up to Ethos to access the full customer list Sign up to Ethos | Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. | Source |
Sign up to Ethos to access the full customer list, plus detailed competitor and product analysis.
Sign up to Ethos